N- Acetylcysteine in Airway Clearance in Broncheictasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: N Acetyle cysteine given by IV injection, Nebulized N Acetyle cysteine.
- Who it may be relevant to
- Registry conditions: Broncheictasis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Broncheictasis
Overview
It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity. Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis
Interventions
- Drug N Acetyle cysteine given by IV injection
Arm: IV N Acetyle cysteine - Drug Nebulized N Acetyle cysteine
Arm: Nebulized N Acetyle cysteine
Primary outcome measures
- sputum viscosity score [Time frame: At the end of 1 week of treatment]
- Amount of sputum [Time frame: At the end of 1 week treatment]
- Expectoration difficulty score [Time frame: At the end of 1 week of treatment]
Secondary outcome measures (1)
- Need for mechanical ventilation [Time frame: At the end of 1 week of treatment]
Eligibility criteria
Inclusion criteria
- Subjects aged above 18 years old; with a diagnosis of bronchiectasis who are admitted to chest department due to acute exacerbation
Exclusion criteria
- current smokers, a known allergy to N-acetylcysteine; pregnancy or lactation (for women); primary diagnosis of COPD or asthma
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07293884 · NAcetylcysteine broncheictasis